As an immune checkpoint molecule on immunosuppressive B-cells, TIM-1 holds promise for guiding the development of new combination therapies that enhance the efficacy of STING agonists, offering new hope for the immunotherapy of HCC. This evidence concerns the gene HAVCR1 and hepatocellular carcinoma.